Atossa Therapeutics, Inc. to Present at the 22nd Annual BIO CEO & Investor Conference
February 05 2020 - 8:00AM
Atossa Therapeutics, Inc. (NASDAQ:
ATOS), a
clinical-stage biopharmaceutical company developing novel
therapeutics and delivery methods for breast cancer and other
breast conditions, today announced that Kyle Guse, CFO will present
a corporate overview at the 22nd Annual BIO CEO & Investor
Conference being held on February 10 and 11, 2020, at the New York
Marriott Marquis in New York City. Mr. Guse will present on
Tuesday, February 11, 2020, at 10:45 am ET, in the Ziegfeld room.
Mr. Guse will also be available for one-on-one meetings on February
11, 2020.
Investors or others interested in meeting with management are
encouraged to request a meeting through the conference’s one-on-one
meetings system or contact Chuck Bennett of CoreIR at
cb@coreir.com.
About the BIO CEO & Investor Conference
The BIO CEO & Investor Conference is one of the largest
investor conferences focused on established and emerging publicly
traded and select private biotech companies. Each year, the BIO CEO
& Investor Conference provides a forum where institutional
investors, industry analysts, and senior biotechnology executives
have the opportunity to meet.
About Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing novel therapeutics and delivery methods to treat
breast cancer and other breast conditions. For more information,
please visit www.atossatherapeutics.com.
Forward-Looking Statements
Forward-looking statements in this press release, which Atossa
undertakes no obligation to update, are subject to risks and
uncertainties that may cause actual results to differ materially
from the anticipated or estimated future results, including the
risks and uncertainties associated with any variation between
preliminary and final clinical results, actions and inactions by
the FDA, the outcome or timing of regulatory approvals needed by
Atossa including those needed to commence studies, lower than
anticipated rate of patient enrollment, estimated market size of
drugs under development, the safety and efficacy of Atossa's
products and services, performance of clinical research
organizations and investigators, obstacles resulting from
proprietary rights held by others with respect to fulvestrant, such
as patent rights, potential market sizes for Atossa's drugs under
development and other risks detailed from time to time in Atossa's
filings with the Securities and Exchange Commission, including
without limitation its periodic reports on Form 10-K and 10-Q, each
as amended and supplemented from time to time.
Atossa Therapeutics Company Contact:
Atossa Therapeutics, Inc.Kyle GuseCFO and General Counsel(O)
800-351-3902kyle.guse@atossainc.com
Investor Relations Contact:
Scott GordonCoreIR377 Oak StreetConcourse 2Garden City, NY
11530Office: 516.222.2560scottg@CoreIR.com
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Apr 2023 to Apr 2024